Final Programme

Scientific Programme Sunday, April 2, 2006
O74 Efficacy of the use of through-catheter
09:42 leukocyte cytospin blood culture for
monitoring haemodialysis catheter
colonisation. A prospective study designed
to prevent bloodstream-related infections
J.L. del Pozo, A. Aguinaga, M. Alonso, A. Serrera,
S. Hernaez, M.J. Garrido, N. García-Fernández,
J. Leiva (Pamplona, ES)
O75 Risk factors and treatment outcome of
09:54 bloodstream infections caused by
Pseudomonas aeruginosa isolates producing
the PER-1 extended-spectrum beta-lactamase
A. Endimiani, B. Pini, F. Luzzaro, G. Amicosante,
G.M. Rossolini, A. Toniolo (Varese, L’Aquila,
Siena, IT)
O76 Is transmission of MRSA frequent between
10:06 patients sharing the same hospital room?
D.S. Blanc, C. Balmelli, C. Petignat, G. Zanetti,
P. Francioli (Lausanne, CH)
O77 Outbreak of Burkolderia cenocepacia
10:18 bacteraemia associated with disinfection
napkin contamination in haemodialysis
M. Solbiati, B. Allegranzi, G. Lo Cascio,
M.G. Bonora, C. Loschiavo, N. Tessitore,
R. Fontana, E. Concia (Verona, IT)
Integrated Symposia
Athena Tailoring initial antifungal therapy
08:30– according to epidemiological trends
10:30– Chairpersons: Oliver Cornely (Cologne, DE)
Pierre Dellamonica (Nice, FR)
08:30 Opening remarks
Pierre Dellamonica (Nice, FR)
S78 Redefining the impact of antifungal
08:40 prophylaxis in high-risk patients
Oliver Cornely (Cologne, DE)
S79 Strategies for antifungal therapy in high-risk
09:10 patients: can we change what we are doing?
Christopher Kibbler (London, UK)
S80 Improving treatment decisions for antifungal
09:40 therapy: what tools are available?
Dimitrios Kontoyiannis (Houston, US)
10:10 Panel discussion
10:25 Closing remarks
Oliver Cornely (Cologne, DE)
Integrated symposium arranged by
Schering-Plough
Méditerranée 1 The challenge for antibiotic therapy in
08:30– treating complicated infections:
10:30 how broad is enough?
Chairpersons: Anthony Berendt (Oxford, UK)
Yehuda Carmeli (Tel Aviv, IL)
08:30 Opening remarks
Anthony Berendt (Oxford, UK)
S81 The change of epidemiology of
08:40 Gram-negative infections
Peter Hawkey (Birmingham, UK)
S82 The role of carbapenems in managing
09:00 Gram-negative infections
Yehuda Carmeli (Tel Aviv, IL)
S83 The role of ertapenem in the management of
09:20 diabetic foot infections
Benjamin Lipsky (Seattle, US)
09:40 Panel discussion
10:20 Closing remarks
Anthony Berendt (Oxford, UK)
Yehuda Carmeli (Tel Aviv, IL)
Integrated symposium arranged by
Merck, Sharp & Dohme
Clio In antimicrobial therapy «use the best one
08:30– first»: examining the evidence
10:30 Chairpersons: Patrick Francioli (Lausanne, CH)
Donald Low (Toronto, CA)
08:30 Introduction
Donald Low (Toronto, CA)
Patrick Francioli (Lausanne, CH)
S84 Differentiating antibiotics on basis of
08:40 preclinical data – determining superior
antimicrobial activity
Francesco Blasi (Milan, IT)
S85 Treatment of lower respiratory tract
09:10 infections – assessing clinical superiority
Robert Read (Sheffield, UK)
S86 Treatment of surgical infections including
09:40 SSSIs – assessing clinical superiority
Johannes Bogner (Munich, DE)
10:10 Panel discussion
10:20 Conclusions
Donald Low (Toronto, CA)
Patrick Francioli (Lausanne, CH)
Integrated symposium arranged by
Bayer HealthCare AG
www.escmid.org/eccmid2006 page 37